Effect of human serum albumin on transplacental transfer of glyburide

Tatiana Nanovskaya, Ilona Nekhayeva, Gary Hankins, Mahmoud Ahmed

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Glyburide is a second-generation sulfonylurea hypoglycemic drug used for the treatment of select women with pregestational and gestational diabetes mellitus (GDM). In vitro and in vivo investigations demonstrated its very low transplacental transfer to the fetal circulation. However, the factors influencing its low transfer across the human placenta remain unclear. Therefore, the goal of the current investigation was to determine the effect of human serum albumin (HSA) on the transfer and distribution of glyburide across the human placenta. To achieve this goal, the technique of dual perfusion of the placental lobule was utilized. The effect of HSA on the transfer of glyburide was determined at the range of glyburide to HSA molar ratios of 1:2-1:100. The transfer rate of free/unbound glyburide to the fetal circuit was 73 ± 10% of the freely diffusible marker compound antipyrine (AP). Data obtained indicates the dependence of glyburide transfer and its retention by the placental tissue on the concentration of HSA.

Original languageEnglish (US)
Pages (from-to)632-639
Number of pages8
JournalBiochemical Pharmacology
Volume72
Issue number5
DOIs
StatePublished - Aug 28 2006

Fingerprint

Glyburide
Serum Albumin
Placenta
Antipyrine
Gestational Diabetes
Medical problems
Hypoglycemic Agents
Perfusion
Tissue
Networks (circuits)

Keywords

  • Dual perfusion
  • Gestational diabetes
  • Glyburide
  • Human placenta
  • Human serum albumin
  • Transplacental transfer

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effect of human serum albumin on transplacental transfer of glyburide. / Nanovskaya, Tatiana; Nekhayeva, Ilona; Hankins, Gary; Ahmed, Mahmoud.

In: Biochemical Pharmacology, Vol. 72, No. 5, 28.08.2006, p. 632-639.

Research output: Contribution to journalArticle

@article{9bc48abf9786493a80f99ca46686f07f,
title = "Effect of human serum albumin on transplacental transfer of glyburide",
abstract = "Glyburide is a second-generation sulfonylurea hypoglycemic drug used for the treatment of select women with pregestational and gestational diabetes mellitus (GDM). In vitro and in vivo investigations demonstrated its very low transplacental transfer to the fetal circulation. However, the factors influencing its low transfer across the human placenta remain unclear. Therefore, the goal of the current investigation was to determine the effect of human serum albumin (HSA) on the transfer and distribution of glyburide across the human placenta. To achieve this goal, the technique of dual perfusion of the placental lobule was utilized. The effect of HSA on the transfer of glyburide was determined at the range of glyburide to HSA molar ratios of 1:2-1:100. The transfer rate of free/unbound glyburide to the fetal circuit was 73 ± 10{\%} of the freely diffusible marker compound antipyrine (AP). Data obtained indicates the dependence of glyburide transfer and its retention by the placental tissue on the concentration of HSA.",
keywords = "Dual perfusion, Gestational diabetes, Glyburide, Human placenta, Human serum albumin, Transplacental transfer",
author = "Tatiana Nanovskaya and Ilona Nekhayeva and Gary Hankins and Mahmoud Ahmed",
year = "2006",
month = "8",
day = "28",
doi = "10.1016/j.bcp.2006.05.019",
language = "English (US)",
volume = "72",
pages = "632--639",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Effect of human serum albumin on transplacental transfer of glyburide

AU - Nanovskaya, Tatiana

AU - Nekhayeva, Ilona

AU - Hankins, Gary

AU - Ahmed, Mahmoud

PY - 2006/8/28

Y1 - 2006/8/28

N2 - Glyburide is a second-generation sulfonylurea hypoglycemic drug used for the treatment of select women with pregestational and gestational diabetes mellitus (GDM). In vitro and in vivo investigations demonstrated its very low transplacental transfer to the fetal circulation. However, the factors influencing its low transfer across the human placenta remain unclear. Therefore, the goal of the current investigation was to determine the effect of human serum albumin (HSA) on the transfer and distribution of glyburide across the human placenta. To achieve this goal, the technique of dual perfusion of the placental lobule was utilized. The effect of HSA on the transfer of glyburide was determined at the range of glyburide to HSA molar ratios of 1:2-1:100. The transfer rate of free/unbound glyburide to the fetal circuit was 73 ± 10% of the freely diffusible marker compound antipyrine (AP). Data obtained indicates the dependence of glyburide transfer and its retention by the placental tissue on the concentration of HSA.

AB - Glyburide is a second-generation sulfonylurea hypoglycemic drug used for the treatment of select women with pregestational and gestational diabetes mellitus (GDM). In vitro and in vivo investigations demonstrated its very low transplacental transfer to the fetal circulation. However, the factors influencing its low transfer across the human placenta remain unclear. Therefore, the goal of the current investigation was to determine the effect of human serum albumin (HSA) on the transfer and distribution of glyburide across the human placenta. To achieve this goal, the technique of dual perfusion of the placental lobule was utilized. The effect of HSA on the transfer of glyburide was determined at the range of glyburide to HSA molar ratios of 1:2-1:100. The transfer rate of free/unbound glyburide to the fetal circuit was 73 ± 10% of the freely diffusible marker compound antipyrine (AP). Data obtained indicates the dependence of glyburide transfer and its retention by the placental tissue on the concentration of HSA.

KW - Dual perfusion

KW - Gestational diabetes

KW - Glyburide

KW - Human placenta

KW - Human serum albumin

KW - Transplacental transfer

UR - http://www.scopus.com/inward/record.url?scp=33746767522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746767522&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2006.05.019

DO - 10.1016/j.bcp.2006.05.019

M3 - Article

VL - 72

SP - 632

EP - 639

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 5

ER -